ARCA biopharma, Inc. (ABIO)
- Previous Close
3.4000 - Open
3.4500 - Bid 3.2400 x 100
- Ask 3.3700 x 100
- Day's Range
3.2106 - 3.5142 - 52 Week Range
1.5600 - 3.8800 - Volume
67,689 - Avg. Volume
1,480,875 - Market Cap (intraday)
48.164M - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4200 - Earnings Date Jul 19, 2024 - Jul 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
www.arcabio.comRecent News: ABIO
Performance Overview: ABIO
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABIO
Valuation Measures
Market Cap
49.32M
Enterprise Value
13.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.67%
Return on Equity (ttm)
-15.87%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6M
Diluted EPS (ttm)
-0.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
35.9M
Total Debt/Equity (mrq)
0.14%
Levered Free Cash Flow (ttm)
-3.84M
Research Analysis: ABIO
Company Insights: ABIO
ABIO does not have Company Insights